102422-56-0

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Fluorobenzyl isocyanate is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications. Its unique structure allows for the creation of molecules with specific biological activities, enhancing the range of treatments available for different medical conditions.
Used in Agrochemical Production:
In the agrochemical industry, 3-Fluorobenzyl isocyanate is utilized as a precursor in the production of pesticides and other crop protection agents. Its incorporation into these compounds can improve their effectiveness in controlling pests and diseases, thereby contributing to increased crop yields and food security.
Used in Organic Synthesis as a Reagent:
3-Fluorobenzyl isocyanate serves as a valuable reagent in organic synthesis, particularly for the preparation of amides, carbamates, and ureas. These compounds are essential in various chemical processes and can be used as building blocks for more complex organic molecules, expanding the scope of chemical research and development.
Safety Precautions:
Given its potent skin and eye irritant properties, 3-Fluorobenzyl isocyanate requires careful handling. It should be used in a well-ventilated environment, and individuals working with this chemical should wear appropriate protective equipment, including gloves, goggles, and masks, to minimize the risk of exposure and potential health hazards.

InChI:InChI=1/C8H6FNO/c9-8-3-1-2-7(4-8)5-10-6-11/h1-4H,5H2

Upstream product

• 100-82-3 (3-fluorophenyl)methanamine 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 331-25-9 (3-fluorophenyl)acetic acid 
• 403-54-3 m-Fluorobenzonitrile 

Downstream Products

• 110-86-1 pyridine 
• 63746-12-3 dimethyl 4-aminoisophthalate 
• 581811-10-1 N-(3-fluorobenzyl)-N'-(3-methyl-5-isoquinolinyl)urea 
• 919120-08-4 C₂₇H₃₇FN₄O₂ 
• 919120-07-3 C₂₇H₃₇FN₄O₂ 
• 1005205-56-0 2-(2,3-dihydro-1-benzofuran-5-ylcarbonyl)-N-(3-fluorobenzyl)hydrazinecarboxamide 
• 917889-30-6 3-(3-fluoro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid methyl ester 
• 1003604-66-7 tert-butyl 3-tert-butoxycarbonylamino-6-ethoxy-7-fluoro-5-[3-(3-fluorobenzyl)ureido]indazole-1-carboxylate 
• 1438000-08-8 N-(3-fluorobenzyl)benzisothiazol-3-one-2-amide 
• 102422-31-1 C₈H₇FNO₄S^(1-)*K⁽¹⁺⁾ 
• 102422-33-3 Imidazole-1-carboxylic acid 3-fluoro-benzylamide 

Relevant academic research and scientific papers

Amide compound, pharmaceutical composition, preparation method and application thereof

The invention provides an amide compound, a pharmaceutical composition, a preparation method and application thereof and belongs to the field of medicine. Structure of the amide compound is shown as aformula I. The preparation method includes: in an alkaline condition and in an organic solvent, allowing a compound I and a compound II to be in condensation reaction. The amide compound or pharmaceutically acceptable salt thereof have long-acting sensory and/or motion blocking activity, can be used for preparing long-acting local anesthetic or analgesic and is long in efficacy lasting time, little side effect and high in medication safety.

Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepines

Judicial structural modifications of 5:7-fused ring-expanded nucleosides (RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic heterocycle (1). The latter exhibited promising broad-spectrum in vitro anti-cancer activity against a number of cancer cell lines screened. This paper describes our systematic, albeit limited, structure-activity relationship (SAR) studies on this lead compound, which produced a number of analogs with broad-spectrum in vitro anti-cancer activities against lung, breast, prostate, and ovarian cancer cell lines, in particular compounds 15i, 15j, 15m and 15n which showed IC 50 values in submicromolar to micromolar range, and are worthy of further explorations. The SAR data also enabled us to propose a tentative SAR model for future SAR efforts for ultimate realization of optimally active and minimally toxic anti-cancer compounds based on the diimidazo[4,5-d:4′, 5′-f][1,3]diazepine structural skeleton of the lead compound 1.

Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors

A number of 1,2-benzisothiazol-3-one derivatives were prepared through structural modification of the original compound from high-throughput screening. Some analogues (e.g., 6b, 6r, 6s and 6w) were identified as novel and potent caspase inhibitors with IC50 of nanomolar. Structure-activity relationship (SAR) studies for caspase-3 inhibition were evaluated in vitro. Molecular modeling studies provided further insight into the interaction of this class of compounds with activated caspase-3. The present small molecule caspase-3 inhibitor with novel structures different from structures of known caspase inhibitors revealed a new direction for therapeutic strategies directed against diseases involving abnormally up-regulated apoptosis.

Development of synthetic aminopeptidase N/CD13 inhibitors to overcome cancer metastasis and angiogenesis

Cancer metastasis is a major barrier to its treatment and an important cause of patient death. Antimetastatic agents hold promise for patients with advanced metastatic tumors. Aminopeptidase N/CD13 (APN) is being pursued by many as an important target against cancer metastasis and angiogenesis, but there are few reports on the in vivo evaluation of synthetic APN inhibitors. Herein, a series of compounds targeting APN were synthesized and evaluated for their antimetastasis and antiangiogenesis potency both in vitro and in vivo. Excitingly, compounds 4m, 4t, and 4cc, with the most potent APN inhibitory activities, displayed significant antimetastasis and antiangiogenesis effects in vitro and in vivo, suggesting that those synthetic APN inhibitors have the potential to overcome cancer metastasis and angiogenesis.

Inactivation of Leukocyte Elastase by Aryl Azolides and Sulfonate Salts. Structure-Activity Relationship Studies

The inhibitory activity of a series of aryl azolides and sulfonate salts toward human leukocyte elastase is reported.Several of the compounds were found to be potent inhibitors of the enzyme.Active compounds were obtained only when the specificity group and the reactive moiety were separated by a two-carbon chain.The introduction of hydrophobic groups enhanced the inhibitory activity of these compounds, with the exception of the sulfonate salts.The nature of the leaving group had had a profound effect on inhibitory activity, with compounds 23 and 26 being the most active (kobsd/ = 11722 and 13500 M-1 s-1, respectively).